Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 92
Filter
2.
J Oral Rehabil ; 34(10): 724-32, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17824884

ABSTRACT

Polypharmacy is a common cause of salivary hypofunction, producing symptoms of dry mouth or xerostomia, especially among older populations. As the number of older people continues to increase, polypharmacy-induced salivary hypofunction is becoming an increasing problem. Many over-the-counter products are available for relieving symptoms of dry mouth, but few have been tested in controlled clinical investigations. The purpose of this investigation was to evaluate the safety and efficacy of a group of topical dry mouth products (toothpaste, mouth rinse, mouth spray and gel) containing olive oil, betaine and xylitol. Forty adults were entered into this single-blinded, open-label, cross-over clinical study and 39 completed all the visits. Subjects were randomly assigned at baseline to using the novel topical dry mouth products daily for 1 week, or to maintain their normal dry mouth routine care. After 1 week, they were crossed over to the other dry mouth regimen. The results demonstrated that the use of the novel topical dry mouth products increased significantly unstimulated whole salivary flow rates, reduced complaints of xerostomia and improved xerostomia-associated quality of life. No clinically significant adverse events were observed. These data suggest that the daily use of topical dry mouth products containing olive oil, betaine and xylitol is safe and effective in relieving symptoms of dry mouth in a population with polypharmacy-induced xerostomia.


Subject(s)
Polypharmacy , Xerostomia/drug therapy , Aged , Betaine/therapeutic use , Cross-Over Studies , Drug Combinations , Female , Humans , Male , Middle Aged , Mouthwashes , Olive Oil , Plant Oils/therapeutic use , Quality of Life , Severity of Illness Index , Single-Blind Method , Toothpastes , Treatment Outcome , Xerostomia/chemically induced , Xylitol/therapeutic use
4.
J Dent Res ; 82(10): 844-8, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14514768

ABSTRACT

A loss of acinar cells occurs with aging, while salivary production remains age-stable in healthy adults. It is hypothesized that a secretory reserve exists to preserve function despite a loss of acinar cells in normal aging. The purpose of this double-blind, placebo-controlled, crossover study was to determine age-related differences in salivary response to an anti-sialogogue (glycopyrrolate). Thirty-six healthy subjects (18 young--20-38 yrs; 18 older--60-77 yrs) received 4.0 microg/kg i.v. glycopyrrolate. Parotid and submandibular/sublingual saliva samples and xerostomia questionnaire responses were collected. Variables calculated for each subject were: times to initial and maximum suppression and xerostomic complaint; time to recovery; and durations of suppression and complaint. Salivary function was more adversely affected in older persons. There were no consistent age-associated questionnaire response differences. These findings suggest that salivary gland output is more adversely affected by an anti-sialogogue in healthy older vs. younger adults, supporting the secretory reserve hypothesis of salivary function.


Subject(s)
Aging/physiology , Salivary Glands/metabolism , Adult , Aged , Cross-Over Studies , Double-Blind Method , Female , Follow-Up Studies , Glycopyrrolate/pharmacology , Humans , Male , Middle Aged , Muscarinic Antagonists/pharmacology , Parotid Gland/drug effects , Placebos , Salivary Glands/drug effects , Salivation/drug effects , Statistics, Nonparametric , Sublingual Gland/drug effects , Submandibular Gland/drug effects , Time Factors , Xerostomia/chemically induced
7.
Semin Radiat Oncol ; 11(3): 234-9, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11447580

ABSTRACT

Recent efforts to reduce xerostomia associated with irradiation (RT) of head and neck cancer include the use of conformal and intensity-modulated RT (IMRT) to partly spare the major salivary glands, notably the parotid glands, from a high radiation dose while treating adequately all the targets at risk of disease. Knowledge of the dose-volume-response relationships in the salivary glands would determine treatment planning goals and facilitate optimization of the RT plans. Recent prospective studies of salivary flows following inhomogeneous irradiation of the parotid glands have utilized dose-volume histograms (DVHs) and various models to assess these relationships. These studies found that the mean dose to the gland is correlated with the reduction of the salivary output. This is consistent with a pure parallel architecture of the functional subunits (FSUs) of the salivary glands. The range of the mean doses, which have been found in these studies to cause significant salivary flow reduction is 26 to 39 Gy.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Parotid Gland/radiation effects , Dose-Response Relationship, Radiation , Humans , Radiotherapy/adverse effects , Xerostomia/chemically induced
8.
Int J Radiat Oncol Biol Phys ; 50(3): 695-704, 2001 Jul 01.
Article in English | MEDLINE | ID: mdl-11395238

ABSTRACT

PURPOSE: To assess long-term xerostomia in patients receiving parotid-sparing radiation therapy (RT) for head-and-neck cancer, and to find the patient and therapy-related factors that affect its severity. PATIENTS AND METHODS: From March 1994 through January 2000, 84 patients received comprehensive bilateral neck RT using conformal and multisegmental intensity-modulated RT (IMRT) aiming to spare the major salivary glands. Before RT and periodically through 2 years after the completion of RT, salivary flow rates from each of the major salivary glands were selectively measured. At the same time intervals, each patient completed an 8-item self-reported xerostomia-specific questionnaire (XQ). To gain a relative measure of the effect of RT on the minor salivary glands, whose output could not be measured, the surfaces of the oral cavity (extending to include the surface of the base of tongue) were outlined in the planning CT scans. The mean doses to the new organ ("oral cavity") were recorded. Forty-eight patients receiving unilateral neck RT were similarly studied and served as a benchmark for comparison. Factors predicting the XQ scores were analyzed using a random-effects model. RESULTS: The XQ was found to be reliable and valid in measuring patient-reported xerostomia. The spared salivary glands which had received moderate doses in the bilateral RT group recovered to their baseline salivary flow rates during the second year after RT, and the spared glands in the unilateral RT group, which had received very low doses, demonstrated increased salivary production beyond their pre-RT levels. The increase in the salivary flow rates during the second year after RT paralleled an improvement in xerostomia in both patient groups. The improvement in xerostomia was faster in the unilateral compared with the bilateral RT group, but the difference narrowed at 2 years. The major salivary gland flow rates had only a weak correlation with the xerostomia scores. Factors found to be independently associated with the xerostomia scores were the pre-RT baseline scores, the time since RT, and the mean doses to the major salivary glands (notably to the submandibular glands) and to the oral cavity. CONCLUSION: An improvement over time in xerostomia, occurring in tandem with rising salivary production from the spared major salivary glands, suggests a long-term clinical benefit from their sparing. The oral cavity mean dose, representing RT effect on the minor salivary glands, was found to be a significant, independent predictor of xerostomia. Thus, in addition to the major salivary glands, sparing the uninvolved oral cavity should be considered as a planning objective to further reduce xerostomia.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Parotid Gland/radiation effects , Radiation Protection , Xerostomia/etiology , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Parotid Gland/metabolism , Radiotherapy, Conformal/adverse effects , Risk Factors , Salivation/radiation effects , Submandibular Gland/metabolism , Submandibular Gland/radiation effects
9.
Article in English | MEDLINE | ID: mdl-11250628

ABSTRACT

OBJECTIVE: This study's objective was to develop a Visual Analogue Scale (VAS) xerostomia questionnaire and to evaluate the validity and reliability for the clinical diagnosis of salivary gland dysfunction. STUDY DESIGN: Thirty-six healthy adults participated in this double-blind, crossover study. Each subject received an antisialagogue (glycopyrrolate) or placebo. Unstimulated and stimulated parotid and submandibular saliva samples were collected 16 times over a period of 6 hours. An 8-item VAS xerostomia questionnaire was administered after each saliva collection. RESULTS: The results demonstrated significant reliability for 7 of the 8 VAS items, whereas validity was significant for unstimulated submandibular saliva. Moving averages were calculated for VAS and salivary flow rate values, and significant correlations were observed between these factors, indicating that changes in VAS responses were predictive of changes in salivary flow. CONCLUSIONS: These findings suggest that this VAS xerostomia questionnaire may be helpful in the diagnosis of salivary dysfunction and for detecting changes in salivary flow rate values over time.


Subject(s)
Diagnosis, Oral/methods , Saliva/metabolism , Surveys and Questionnaires , Xerostomia/diagnosis , Adult , Aged , Cross-Over Studies , Double-Blind Method , Female , Glycopyrrolate/pharmacology , Humans , Male , Middle Aged , Muscarinic Antagonists/pharmacology , Reproducibility of Results , Saliva/drug effects , Secretory Rate/drug effects , Statistics, Nonparametric
10.
Article in English | MEDLINE | ID: mdl-11174593

ABSTRACT

OBJECTIVE: Many diabetics complain of xerostomia, a condition that can affect oral health, nutritional status, and diet selection. This study's purposes were (1) to investigate the effect on salivary flow of type 2 diabetes and change in glycemic control in a group of older adults over time and (2) to compare flow rates with subjective complaints of xerostomia. STUDY DESIGN: A total of 39 older adults, 24 with type 2 diabetes and 15 who were nondiabetic (controls), aged 54-90 years, participated in a 1-year follow-up study. Diabetic status was determined by means of glycosylated hemoglobin (HbA1c) levels and 2-hour glucose tolerance tests. Poor glycemic control was defined as HbA1c > 9%. Unstimulated whole, unstimulated parotid, and stimulated parotid saliva flow rates were measured for all subjects by a single examiner at baseline and 1 year later. Each subject completed a standardized xerostomia questionnaire at every visit. RESULTS: Age, sex, and duration of diabetes did not adversely affect salivary flow rates. Subjects with poorly controlled diabetes had significantly lower stimulated parotid saliva flow rates at both visits. There were no significant changes in flow rates over time on the basis of diabetic status or glycemic control. Subjects with diabetes reported significantly more complaints of thirst but not of xerostomia at 1 year. CONCLUSIONS: These results suggest that older adults with poorly controlled diabetes may have impaired salivary flow in comparison with subjects with better controlled diabetes and nondiabetic subjects, yet they may not have concomitant xerostomic complaints. There were no significant changes in salivary flow rates or glycemic control over the 1-year period.


Subject(s)
Diabetes Mellitus, Type 2/physiopathology , Saliva/metabolism , Aged , Aged, 80 and over , Analysis of Variance , Blood Glucose/analysis , Chi-Square Distribution , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/prevention & control , Feeding Behavior , Female , Follow-Up Studies , Glucose Tolerance Test , Glycated Hemoglobin/analysis , Humans , Longitudinal Studies , Male , Middle Aged , Nutritional Status , Parotid Gland/metabolism , Secretory Rate/physiology , Statistics, Nonparametric , Thirst/physiology , Time Factors , Xerostomia/physiopathology
11.
Oral Oncol ; 37(1): 84-93, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11120488

ABSTRACT

Radiotherapy (RT) for head and neck cancers causes salivary dysfunction and diminished xerostomia-related quality of life. We have demonstrated that three-dimensional treatment planning and conformational dose-delivery techniques can minimize RT doses to contralateral parotid glands while providing therapeutic doses to tumors. This study's purpose was to assess parotid salivary function up to 1 year post-RT in patients receiving bilateral neck parotid-sparing RT, and to determine if parotid preservation would significantly improve xerostomia-related quality of life. Unstimulated (UPFR) and stimulated (SPFR) parotid flow rates were collected from 20 head and neck cancer patients. All subjects completed a 15-item xerostomia-related quality of life scale (XeQoLS) prior to RT, at the completion of RT, 1, 3, 6 and 12 months post-RT. Salivary flow rates from spared and treated glands were significantly decreased at the completion of RT. After RT completion, spared UPFR and SPFR function increased and was not significantly different from baseline values. Output from treated glands remained statistically indistinguishable from zero throughout the post-RT period. Subjects had a significantly worse xerostomia-related quality of life at the completion of RT compared to baseline, and XeQoLS responses improved significantly 1 month post-RT. Responses at 1 year were markedly better than at the completion of RT, but still significantly worse than baseline. These findings suggest that despite parotid-sparing RT, salivary flow rates from treated and spared glands and xerostomia-related quality of life decrease at the completion of RT. However, with the use of parotid-sparing RT, contralateral glands are preserved at 1 year post-RT with a concomitant improvement in xerostomia-related quality of life.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Quality of Life , Radiation Injuries/prevention & control , Salivation/radiation effects , Xerostomia/prevention & control , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Head and Neck Neoplasms/rehabilitation , Health Status Indicators , Humans , Male , Middle Aged , Oral Health , Parotid Gland/metabolism , Parotid Gland/radiation effects , Radiation Dosage , Radiotherapy Planning, Computer-Assisted/methods , Surveys and Questionnaires , Xerostomia/etiology
12.
Spec Care Dentist ; 21(5): 187-90, 2001.
Article in English | MEDLINE | ID: mdl-11803643

ABSTRACT

This case report describes a 14-year-old female referred to Pediatric Dentistry for evaluation and treatment of cyclosporine-induced gingival hyperplasia. Examination of the anterior maxillary area showed a red, vascular, exophytic, soft-tissue mass which had been excised a few months earlier without a histopathologic examination being done. The mass did not appear consistent with gingival overgrowth induced by long-term use of medication, and thus an excisional biopsy was performed, which diagnosed the lesion as a pyogenic granuloma. A review of the literature and management recommendations are discussed.


Subject(s)
Dental Care for Chronically Ill , Granuloma, Pyogenic/diagnosis , Kidney Transplantation , Periapical Granuloma/diagnosis , Adolescent , Cyclosporine/adverse effects , Diagnosis, Differential , Female , Gingival Hyperplasia/chemically induced , Gingival Hyperplasia/complications , Gingival Hyperplasia/diagnosis , Granuloma, Pyogenic/complications , Humans , Immunosuppressive Agents/adverse effects , Periapical Granuloma/complications
13.
Spec Care Dentist ; 21(5): 176-81, 2001.
Article in English | MEDLINE | ID: mdl-11803641

ABSTRACT

Complaints of xerostomia and salivary hypofunction are common in older adults. However, recent studies reported that dehydration-induced salivary hypofunction caused fewer xerostomic complaints in older compared with young adults. This may predispose older adults to developing oral problems that will subsequently not receive attention from health care providers. Since many medications are known to inhibit salivation, this study attempted to determine if an anticholinergic drug (glycopyrrolate) had a differential effect on xerostomic complaints in young vs. older adults. Eighteen young (age 20-38 yrs) and 18 older (age 60-77 yrs) healthy adults were given a 4.0 micrograms/kg dose of i.v. glycopyrrolate. For 6 hrs after drug administration, stimulated parotid salivary flow was collected, and an eight-item Visual Analogue Scale (VAS) subjective xerostomia test was given. At several time points post-i.v. glycopyrrolate, salivary flow rates were consistently lower in older compared with young adults. For some measures of xerostomic complaint (time to first complaint; time to maximum complaint; mean maximum complaint), there were no age-related differences for all VAS items. However, a trend for increased xerostomic complaints in older adults was demonstrated (time to recovery; total duration of complaint; number xerostomic at 6 hrs). These findings suggest that, given equal doses of an anti-sialogogue, salivary hypofunction is greater in healthy older adults, while increased complaints of xerostomia are not as consistent.


Subject(s)
Glycopyrrolate/adverse effects , Muscarinic Antagonists/adverse effects , Salivation/drug effects , Xerostomia/chemically induced , Adult , Age Factors , Aged , Chi-Square Distribution , Female , Humans , Male , Parotid Gland/metabolism , Secretory Rate/drug effects , Surveys and Questionnaires
14.
Article in English | MEDLINE | ID: mdl-10710454

ABSTRACT

OBJECTIVE: There is no consensus on the possible association between diabetes and salivary dysfunction in older persons with diabetes. This study's purpose was to investigate the effect of diabetes and glycemic control on salivary function in an older population. STUDY DESIGN: Twenty nine persons with type 2 diabetes and 23 nondiabetic control subjects participated (age range, 54-90 years). Diabetic status was determined by a glycosylated hemoglobin (HbA(1c)) test and a 2-hour glucose tolerance test. Poor glycemic control was defined as HbA(1c) >9%. Unstimulated whole saliva, unstimulated parotid, and stimulated parotid flow rates were measured, and subjects completed a standardized xerostomia questionnaire. RESULTS: Persons with poorly controlled diabetes had lower (P =.01) stimulated parotid flow rates than persons with well-controlled diabetes and nondiabetic control subjects. There were no significant differences in xerostomic complaints based on diabetic or glycemic control status or salivary flow rates. CONCLUSIONS: These results provide some evidence that poorly controlled diabetes may be associated with salivary dysfunction in older adults who have no concomitant complaints of xerostomia.


Subject(s)
Blood Glucose/analysis , Diabetes Mellitus, Type 2/physiopathology , Salivary Glands/metabolism , Aged , Aged, 80 and over , Analysis of Variance , Chi-Square Distribution , Cross-Sectional Studies , Diabetes Mellitus, Type 2/prevention & control , Female , Glucose Tolerance Test , Glycated Hemoglobin/analysis , Humans , Male , Middle Aged , Parotid Gland/metabolism , Saliva/metabolism , Salivary Gland Diseases/etiology , Secretory Rate/physiology , Xerostomia/classification , Xerostomia/physiopathology
15.
Int J Radiat Oncol Biol Phys ; 46(5): 1117-26, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10725621

ABSTRACT

PURPOSE: To analyze the patterns of local-regional recurrence in patients with head and neck cancer treated with parotid-sparing conformal and segmental intensity-modulated radiotherapy (IMRT). METHODS AND MATERIALS: Fifty-eight patients with head and neck cancer were treated with bilateral neck radiation (RT) using conformal or segmental IMRT techniques, while sparing a substantial portion of one parotid gland. The targets for CT-based RT planning included the gross tumor volume (GTV) (primary tumor and lymph node metastases) and the clinical target volume (CTV) (postoperative tumor bed, expansions of the GTVs and lymph node groups at risk of subclinical disease). Lymph node targets at risk of subclinical disease included the bilateral jugulodigastric and lower jugular lymph nodes, bilateral retropharyngeal lymph nodes at risk, and high jugular nodes at the base of skull in the side of the neck at highest risk (containing clinical neck metastases and/or ipsilateral to the primary tumor). The CTVs were expanded by 5 mm to yield planning target volumes (PTVs). Planning goals included coverage of all PTVs (with a minimum of 95% of the prescribed dose) and sparing of a substantial portion of the parotid gland in the side of the neck at less risk. The median RT doses to the gross tumor, the operative bed, and the subclinical disease PTVs were 70.4 Gy, 61.2 Gy, and 50.4 Gy respectively. All recurrences were defined on CT scans obtained at the time of recurrence, transferred to the pretreatment CT dataset used for RT planning, and analyzed using dose-volume histograms. The recurrences were classified as 1) "in-field," in which 95% or more of the recurrence volume (V(recur)) was within the 95% isodose; 2) "marginal," in which 20% to 95% of V(recur) was within the 95% isodose; or 3) "outside," in which less than 20% of V(recur) was within the 95% isodose. RESULTS: With a median follow-up of 27 months (range 6 to 60 months), 10 regional recurrences, 5 local recurrences (including one noninvasive recurrence) and 1 stomal recurrence were seen in 12 patients, for a 2-year actuarial local-regional control rate of 79% (95% confidence interval 68-90%). Ten patients (80%) relapsed in-field (in areas of previous gross tumor in nine patients), and two patients developed marginal recurrences in the side of the neck at highest risk (one in the high retropharyngeal nodes/base of skull and one in the submandibular nodes). Four regional recurrences extended superior to the jugulodigastric node, in the high jugular and retropharyngeal nodes near the base of skull of the side of the neck at highest risk. Three of these were in-field, in areas that had received the dose intended for subclinical disease. No recurrences were seen in the nodes superior to the jugulodigastric nodes in the side of the neck at less risk, where RT was partially spared. CONCLUSIONS: The majority of local-regional recurrences after conformal and segmental IMRT were "in-field," in areas judged to be at high risk at the time of RT planning, including the GTV, the operative bed, and the first echelon nodes. These findings motivate studies of dose escalation to the highest risk regions.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Neoplasm Recurrence, Local , Parotid Gland , Radiotherapy, Conformal/methods , Adult , Aged , Aged, 80 and over , Confidence Intervals , Female , Follow-Up Studies , Head and Neck Neoplasms/drug therapy , Humans , Male , Middle Aged , Mouth Neoplasms/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Neoplasm Recurrence, Local/surgery , Prognosis , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Salvage Therapy
16.
J Gerontol A Biol Sci Med Sci ; 55(1): M34-42, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10719771

ABSTRACT

BACKGROUND: Recent investigations have demonstrated that parotid salivary dysfunction is not a normal process of aging, but may be the consequence of systemic conditions and their treatment, including medications and menopause. The purpose of this study was to assess longitudinally the influence of age, menopausal status, hormone replacement therapy, and other medications on stimulated parotid flow rates (SPFRs) in healthy women. METHODS: Medical diagnoses, menopausal status, medication utilization, and 2% citric acid stimulated parotid salivas were collected from 396 women, aged 21 to 96 years, from the Baltimore Longitudinal Study of Aging (National Institute on Aging, National Institutes of Health) over a 17-year span by three investigators. RESULTS: There was no overall longitudinal effect of time on SPFR. Age at first visit was a significant predictor of a decrease in SPFR when adjusted for time and xerostomic medications. However, the deleterious effect of taking one xerostomic medication was equivalent to approximately 14 years of aging. Menopausal status and hormone replacement therapy were not consistently associated with diminished SPFR. CONCLUSIONS: These results suggest that menopause and hormone replacement therapy are not associated with parotid salivary dysfunction. Aging may have a statistically significant yet small deleterious influence on SPFR; however, the adverse influence of xerostomic medications is much larger.


Subject(s)
Aging/physiology , Hormone Replacement Therapy , Menopause/physiology , Parotid Gland/physiology , Salivation/drug effects , Salivation/physiology , Adult , Aged , Aged, 80 and over , Analysis of Variance , Cross-Sectional Studies , Female , Humans , Longitudinal Studies , Middle Aged , Secretory Rate/drug effects , Secretory Rate/physiology
17.
Article in English | MEDLINE | ID: mdl-10630932

ABSTRACT

Older adults are the most rapidly growing segment of the population, and the prevalence of dementia in this cohort is increasing as well. Diagnostic and management strategies for dementia are improving. With significantly more dentate older adults, there will be an increased need in the future for dental care services for the geriatric population with dementia. Research reports demonstrate impaired oral health even in community-dwelling adults with moderate dementia. Therefore, oral health care providers will be increasingly challenged with preserving oral and nutritional health in these patients in order to diminish pain and pathology and to maintain the dignity and quality of life of a person with dementia.


Subject(s)
Dementia , Oral Health , Dementia/diagnosis , Dementia/epidemiology , Dementia/etiology , Dementia/therapy , Dental Care for Disabled , Diagnosis, Differential , Humans
18.
J Dent Res ; 79(11): 1874-8, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11145358

ABSTRACT

Salivary hypofunction is associated with oral and pharyngeal disorders and requires early diagnosis and intervention. Large variability in salivary flow rates within and between individuals has been reported, which has impaired the establishment of standard values. The objective of this study was to determine variations in stimulated parotid and submandibular flow rates over 6 hours and to define salivary hypofunction. Pooled mean, standard deviation, and coefficient of variation values for four collection time periods were obtained from 36 healthy males and females (18 young, ages 20-38; 18 older, ages 60-77). The results demonstrated 27-44% variation in salivary flow rates over time. Overall, there were no significant age or gender differences in variability between and within salivary flow rates at all collection time periods. The results suggest that a 45% range in salivary flow rates could be considered normal salivary variation, and values below 45% of normal levels could be used to define salivary hypofunction.


Subject(s)
Saliva/metabolism , Xerostomia/diagnosis , Adult , Age Factors , Aged , Analysis of Variance , Female , Humans , Male , Middle Aged , Parotid Gland/metabolism , Reference Values , Secretory Rate , Stimulation, Chemical , Submandibular Gland/metabolism
19.
Spec Care Dentist ; 20(3): 81-92, 2000.
Article in English | MEDLINE | ID: mdl-11203886

ABSTRACT

As the population ages, with increased retention of the natural dentition, there will be a greater responsibility for dental professionals to maintain the oral health of medically, behaviorally, cognitively, and physically impaired adults. Oral sedatives and nitrous oxide analgesia are frequently and successfully used for dental treatments in these patients. However, many compromised older adults cannot safely tolerate dental treatment with these sedative techniques in an outpatient setting. This paper describes the use of general anesthesia in a hospital environment, coordinated with medical and anesthesia specialists, that is a viable, safe, and effective treatment tool for providing comprehensive dental and oral surgical treatment for the older patient.


Subject(s)
Anesthesia, Dental/methods , Anesthesia, General/methods , Adult , Aged , Aging/physiology , Ambulatory Care , Analgesics/therapeutic use , Comprehensive Dental Care , Dental Care for Aged , Dental Care for Chronically Ill , Dental Care for Disabled , Dental Records , Dental Service, Hospital , Fees and Charges , Female , Humans , Hypnotics and Sedatives/therapeutic use , Male , Nitrous Oxide/therapeutic use , Oral Surgical Procedures , Patient Care Planning , Patient Care Team , Perioperative Care , Postoperative Care , Preanesthetic Medication , Preoperative Care , Risk Factors , Safety
20.
Quintessence Int ; 31(2): 95-112, 2000 Feb.
Article in English | MEDLINE | ID: mdl-11203919

ABSTRACT

Etiology and Epidemiology: The Greek term aphthai was initially used in relation to disorders of the mouth and is credited to Hippocrates (460-370 BC). Today, recurrent aphthous ulceration, or recurrent aphthous stomatitis (RAS), is recognized as the most common oral mucosal disease known to human beings. Considerable research attention has been devoted to elucidating the causes of RAS; local and systemic conditions, and genetic, immunologic, and infectious microbial factors all have been identified as potential etiopathogenic agents (Table 1). However, to date, no principal etiology has been discovered. Epidemiologic studies indicate that the prevalence of RAS is between 2% and 50% in the general population; most estimates fall between 5% and 25%. In selected groups, such as medical and dental students, it has been observed with a frequency as high as 50% to 60%. The peak age of onset for RAS is between 10 and 19 years. After childhood and adolescence, it may continue throughout the entire human lifespan without geographic or age-, sex-, or race-related preference.


Subject(s)
Stomatitis, Aphthous , Administration, Topical , Anti-Inflammatory Agents/therapeutic use , Glucocorticoids , Humans , Immunosuppressive Agents/therapeutic use , Prevalence , Referral and Consultation , Stomatitis, Aphthous/diagnosis , Stomatitis, Aphthous/epidemiology , Stomatitis, Aphthous/etiology , Stomatitis, Aphthous/therapy , Thalidomide/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...